Epidemiology of prostate cancer in Nigeria: a mixed methods systematic review.

Distribution Epidemiology Gleason score Incidence Nigeria Prevalence Prostate cancer

Journal

Cancer causes & control : CCC

ISSN: 1573-7225

Titre abrégé: Cancer Causes Control

Pays: Netherlands

ID NLM: 9100846

Informations de publication

Date de publication:
22 Sep 2024

Historique:

received: 08 07 2023

accepted: 04 09 2024

medline: 22 9 2024

pubmed: 22 9 2024

entrez: 22 9 2024

Statut: aheadofprint

Résumé

Prostate cancer (PCa) is an increasing burden in Sub-Saharan Africa. This systematic review examined the incidence, prevalence, clinical characteristics and outcomes of PCa in Nigeria. This review followed the standard Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Peer-reviewed observational studies that focused on epidemiology of PCa in Nigeria, published between 1990 and 2023 and written in English were eligible. Combination of keywords was used to search PubMed, Scopus, Google scholar, AJOL and web of science databases. A piloted form by the Cochrane Public Health Group Data Extraction and Assessment Template was used to extract data from retrieved studies. Quality assessment of included studies was performed using the Newcastle-Ottawa scale for observational studies. Of the 1898 articles retrieved, 21 met the inclusion criteria. All included studies showed good quality. Mean age for PCa ranged from 55 to 71 years, with a higher prevalence occurring within 60-69 years. A 7.7 fold increase in PCa incidence was reported for the years 1997-2006, while an average annual increase in incidence rate of 11.95% was observed from 2009 to 2013. Hospital-based prevalence of 14%-46.4% was observed for clinically active PCa. Patients presented for diagnosis with high Gleason scores and advanced PCa. High mortality (15.6%-64.0%) occurred between 6 months and 3 years of diagnosis. Findings suggest rising incidence and high prevalence of PCa in Nigeria. Advanced PCa was most common at diagnosis and mortality was high. There is need for improved strategies and policies for early detection of PCa in Nigeria.

Identifiants

DOI: 10.1007/s10552-024-01917-w PMID: 39306811

pubmed: 39306811

doi: 10.1007/s10552-024-01917-w

pii: 10.1007/s10552-024-01917-w

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492

doi: 10.3322/caac.21492 pubmed: 30207593

Dawam D, Rafindadi AH, Kalayi GD (2000) Benign prostatic hyperplasia and prostate carcinoma in native Africans. BJU Int 85(9):1074–1077. https://doi.org/10.1046/j.1464-410x.2000.00677.x

doi: 10.1046/j.1464-410x.2000.00677.x pubmed: 10848698

Just J, Osgun F, Knight C (2018) Lower urinary tract symptoms and prostate cancer: is PSA testing in men with symptoms wise? Br J Gen Pract 68(676):541–542. https://doi.org/10.3399/bjgp18X699689

doi: 10.3399/bjgp18X699689 pubmed: 30361318 pmcid: 6193782

Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10(2):63–89. https://doi.org/10.14740/wjon1191

doi: 10.14740/wjon1191 pubmed: 31068988 pmcid: 6497009

Taitt HE (2018) Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health 12(6):1807–1823. https://doi.org/10.1177/1557988318798279

doi: 10.1177/1557988318798279 pubmed: 30203706 pmcid: 6199451

Cuzick J, Thorat MA, Androle G, Brawley OW, Brown PH, Culig Z et al (2014) Prevention and early detection of prostate cancer. Lancet Oncol 15(11):e484–e492. https://doi.org/10.1016/S1470-2045(14)70211-6

doi: 10.1016/S1470-2045(14)70211-6 pubmed: 25281467 pmcid: 4203149

Cao L, Zhang S, Jia C, He W, Wu L, Li Y, Wang W, Li Z, Ma J (2018) Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies. BMC Urol 18:17. https://doi.org/10.1186/s12894-018-0318-7

doi: 10.1186/s12894-018-0318-7 pubmed: 29514670 pmcid: 5842557

Siltari A, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A (2020) Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS ONE 15(6):e0234269. https://doi.org/10.1371/journal.pone.0234269

doi: 10.1371/journal.pone.0234269 pubmed: 32598349 pmcid: 7323967

Leitzmann MF, Rohrmann S (2012) Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol 4:1–11. https://doi.org/10.2147/CLEP.S16747

doi: 10.2147/CLEP.S16747 pubmed: 22291478 pmcid: 3490374

Ogunbiyi JO, Shittu OB (1999) Increased incidence of prostate cancer in Nigerians. J Natl Med Assoc 91(3):159–164

pubmed: 10203918 pmcid: 2608450

World Health Organisation (2021) International Agency for Research and Cancer – Global Cancer Observatory. https://gco.iarc.fr/today/data/factsheets/populations/566-nigeria-fact-sheets.pdf . Accessed 27 December 2022.

Oluwole PO, Shehu MS, Samaila MOA (2015) A ten-year study of prostate cancer specimens at Ahmadu Bello University Teaching Hospital (ABUTH), Zaria Nigeria. Afr J Urol 21(1):15–18. https://doi.org/10.1016/j.afju.2014.09.004

doi: 10.1016/j.afju.2014.09.004

Ukah CO, Nwofor AM (2017) Cancer incidence in south-east Nigeria: a report from Nnewi Cancer Registry. Orient J Med 29(1):8

Emiogun FE, Williams OO, Obafunwa JO (2019) Epidemiology of prostate cancer in Nigeria: observations at Lagos State University Teaching Hospital. Cancer Health Disparities 4:1–9. https://doi.org/10.9777/chd.2019.1003

doi: 10.9777/chd.2019.1003

World Health Organisation b. Leading causes of death in Nigeria. 2020. https://www.worldlifeexpectancy.com/nigeria-prostate-cancer#:~:text=According%20to%20the%20latest%20WHO,choose%20the%20full%20health%20profile . Accessed 27th December, 2022.

Ikuerowo SO, Omisanjo OA, Bioku MJ, Ajala MO, Mordi VPN (2013) Esho JO (2013) Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum specific antigen and digital rectal examination. Pan Afr Med J 15:129. https://doi.org/10.11604/pamj.2013.15.129.2489

doi: 10.11604/pamj.2013.15.129.2489 pubmed: 24255735 pmcid: 3830465

Ofoha CG, Magnus FE (2019) Presentations, characteristics and co-morbidities of men with prostate cancer in Nigeria. J Adv Med Med Res 31(5):1–7. https://doi.org/10.9734/jammr/2019/v31i530297

doi: 10.9734/jammr/2019/v31i530297

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) Preferred reporting items for systematic reviews and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1. https://doi.org/10.1186/2046-4053-4-1

doi: 10.1186/2046-4053-4-1 pubmed: 25554246 pmcid: 4320440

Ottawa Hospital Research Institute (2023) https://www.ohri.ca/programs/clinical_epidemiology/nos_manual.pdf . Accessed February 21, 2023.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906

doi: 10.1016/j.ijsu.2021.105906 pubmed: 33789826

Osegbe DN (1997) Prostate cancer in Nigerians: facts and nonfacts. J Urol 157(4):1340–1343

doi: 10.1016/S0022-5347(01)64966-8 pubmed: 9120935

Iyare FE (2008) Diseases of the prostate among Igbos of Southeastern Nigeria. Ebonyi Med J 7(1&2):8–13. https://doi.org/10.4314/ebomed.v7i1.41552

doi: 10.4314/ebomed.v7i1.41552

Anunobi CC, Akinde OR, Elesha SO, Daramola AO, Tijani KH, Ojewola RW (2011) Prostate diseases in Lagos, Nigeria: a histologic study with tPSA correlation. Niger Postgrad Med J 8(2):98–104

doi: 10.4103/1117-1936.170330

Ebughe GA, Ekanem IA, Omoronyia OE, Nnoli MA, Ikpi EE, Ugbem TI (2016) Prostate cancer incidence in Calabar—Nigeria. Br J Med Med Res 14(5):1–10. https://doi.org/10.9734/BJMMR/2016/23503

doi: 10.9734/BJMMR/2016/23503

Adewumi OA, Sowunmi CA, Alabi AS, Fatiregun OA (2016) Ketiku KK (2016) Pattern of prostate cancer among a Nigerian population: a study in a single tertiary care centre. Nig J Med 25(1):70–77

doi: 10.4103/1115-2613.278256

Ajape AA, Ibrahim KOO, Fakeye JA, Abiola OO (2010) An overview of the prostate diagnosis and management in Nigeria: the experience in a Nigerian tertiary hospital. Ann Afr Med 9(3):113–117. https://doi.org/10.4103/1598-3519.68353

doi: 10.4103/1598-3519.68353 pubmed: 20710099

Aligbe JU, Forae GD (2013) Prostatic tumours among Nigerian males: a private practice experience in Benin-City, South-South Nigeria. Nigerian Postgrad. Med J 20(3):193–196

doi: 10.4103/1117-1936.164709

Obiorah CC, Nwosu SO (2011) A histopathological study of carcinoma of the prostate in Port Harcourt, Nigeria. Niger J Clin Pract 14:363–367. https://doi.org/10.4103/1119-3077.86785

doi: 10.4103/1119-3077.86785 pubmed: 22037086

Raheem N, Dahiru AMC (2021) Histopathological pattern of prostate diseases in Yola, Nigeria: a five-year review. Nig J Med 30(4):390–393. https://doi.org/10.4103/NJM.NJM_82_21

doi: 10.4103/NJM.NJM_82_21

Ebughe GA, Ugbem TI, Ushie DE, Effewongbe S (2019) The pattern of cancer cases in the rest of cross river state not covered by the calabar cancer registry between 2004 and 2013. J Adv Med Med Res 30(1):1–8. https://doi.org/10.9734/jammr/2019/v30i130163

doi: 10.9734/jammr/2019/v30i130163

Ugwumba FO, Okoh AD, Echetabu KN, Udeh EI, Nnabugwu II (2017) Prostate cancer detected by screening in a semi urban community in Southeast Nigeria: correlations and associations between anthropometric measurements and prostate-specific antigen. Niger J Surg 23:33–36. https://doi.org/10.4103/1117-6806.199967

doi: 10.4103/1117-6806.199967 pubmed: 28584509 pmcid: 5441213

Ngwogu KO, Ekperi O, Offiah SAU (2019) Prevalence and histopathological patterns of prostate cancer in Abia State University Teaching Hospital, Aba, south eastern Nigeria. Abia State Univ MedStudents’ Assoc J 12(1):8

Akang EE, Aligbe JU, Olisa EG (1996) Prostatic tumours in Benin City. Nigeria West Afr J Med 15(1):56–60

pubmed: 8652442

Ekeke O, Amusan O, Eke N (2012) Management of prostate cancer in Port Harcourt, Nigeria: changing patterns. J West Afr Coll Surg 2(3):58–77

pubmed: 25452994 pmcid: 4240232

Ramaliba TM, Sithole N, Ncinitwa A, Somdyala NIM (2022) Prostate cancer patterns and trends in the eastern cape province of South Africa; 1998–2017. Front Pub Health 10:882586. https://doi.org/10.3389/fpubh.2022.882586

doi: 10.3389/fpubh.2022.882586

Seraphin TP, Joko-Fru WY, Kamaté B, Chokunonga E, Wabinga H, Somdyala NIM, Manraj SS, Ogunbiyi OJ, Dzamalala CP, Finesse A, Korir A, N’Da G, Lorenzoni C, Liu B, Kantelhardt EJ, Parkin DM (2021) Rising Prostate cancer incidence in sub-Saharan Africa: a trend analysis of data from the African cancer registry network. Cancer Epidemiol Biomarkers Prev 30(1):158–165. https://doi.org/10.1158/1055-9965.EPI-20-1005

doi: 10.1158/1055-9965.EPI-20-1005 pubmed: 33033143

Egote AK, Ossei PS, Ayibor WG, Egote CA (2020) Incidence of prostate cancer at a Referral center in the Brong Ahafo region of Ghana: a year retrospective study. World J Adv Res Rev 05(1):050–057. https://doi.org/10.30574/wjarr.2020.5.1.0006

doi: 10.30574/wjarr.2020.5.1.0006

Chidebe RCW, Emelumadu O, Lounsbury D, Orjiakor TC, Okoye IO, Anunobi CD, Hafees A, Ikuerowo SO, Dogo H, Moraes F, Achor G, Eguzo K, Atakere D, Ezeama N, Ugwuoke C, Dantsoho SA, Okoro N, Abdulazeez J, Iriyo I, Emeralds O, Okwuegbunam N (2018) Men on blue: knowledge, belief, fear, perceived attitude of men to prostate cancer screening and awareness in Sub-Saharan Africa. J. Global Oncol 4(Suppl 2):238s. https://doi.org/10.1200/jgo.18.95500

doi: 10.1200/jgo.18.95500

Enemugwem RA, Eze BA, Ejike U et al (2019) Prostate cancer screening: assessment of knowledge and willingness to screen among men in Obio Akpor LGA, Rivers State. Nigeria Afr J Urol 25:11. https://doi.org/10.1186/s12301-019-0010-5

doi: 10.1186/s12301-019-0010-5

Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, Ward EM (2015) Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 314(19):2054–2061. https://doi.org/10.1001/jama.2015.14905

doi: 10.1001/jama.2015.14905 pubmed: 26575061

Sapira MK, Eke N, Nwofor AME (2015) Ethnicity and prostate cancer in Southern Nigeria: a preliminary report. Niger J Surg 21:96–101. https://doi.org/10.4103/1117-6806.162590

doi: 10.4103/1117-6806.162590 pubmed: 26425060 pmcid: 4566329

Bechis SK, Carroll PR, Cooperberg MR (2011) Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 29(2):235–241. https://doi.org/10.1200/JCO.2010.30.2075

doi: 10.1200/JCO.2010.30.2075 pubmed: 21135285

Godtman RA, Kollberg KS, Pihl C, Månsson M, Hugosson J (2022) The association between Age, prostate cancer risk, and higher Gleason score in a long-term screening program: results from the Göteborg-1 prostate cancer screening trial. Eur Urol 82(3):311–317. https://doi.org/10.1016/j.eururo.2022.01.018

doi: 10.1016/j.eururo.2022.01.018 pubmed: 35120773

Kurian CJ, Leader AE, Thong MSY, Keith CW, Zeigler-Johnson CM (2018) Examining relationships between age at diagnosis and health-related quality of life outcomes in prostate cancer survivors. BMC Pub Health 18:1060. https://doi.org/10.1186/s12889-018-5976-6

doi: 10.1186/s12889-018-5976-6

Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P (2018) Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol 29(2):377–385. https://doi.org/10.1093/annonc/mdx742

doi: 10.1093/annonc/mdx742 pubmed: 29161337

Zhu Y, Mo M, Wei Y et al (2021) Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol 18:282–301. https://doi.org/10.1038/s41585-021-00442-8

doi: 10.1038/s41585-021-00442-8 pubmed: 33692499

Seraphin TP, Joko-Fru WY, Manraj SS et al (2021) Prostate cancer survival in sub-Saharan Africa by age, stage at diagnosis, and human development index: a population-based registry study. Cancer Causes Control 32:1001–1019. https://doi.org/10.1007/s10552-021-01453-x

doi: 10.1007/s10552-021-01453-x pubmed: 34244896 pmcid: 8310516

Baade PD, Youlden DR, Krnjacki LJ (2009) International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 53(2):171–184. https://doi.org/10.1002/mnfr.200700511

doi: 10.1002/mnfr.200700511 pubmed: 19101947

Zeigler-Johnson CM, Rennert H, Mittal RD, Jalloh M, Sachdeva R, Malkowicz SB, Mandhani A, Mittal B, Gueye SM, Rebbeck TR (2008) Evaluation of prostate cancer characteristics in four populations worldwide. Can J Urol 15(3):4056–4064

pubmed: 18570709 pmcid: 3072889

Lozano-Lorca M, Barrios-Rodríguez R, Redondo-Sánchez D et al (2022) Health-related quality of life in patients newly diagnosed with prostate cancer: CAPLIFE study. Qual Life Res. https://doi.org/10.1007/s11136-022-03302-z

doi: 10.1007/s11136-022-03302-z pubmed: 36409391 pmcid: 10063519